NLRP3 and Parkinson disease: MCC950, a small molecule inhibitor targeting the NLRP3 inflammasome, has been demonstrated to suppress neuronal damage, attenuate α-syn deposition and inflammation, and alleviate dyskinesia in various PD models, including PFF- and 6-OHDA-treated and α-syn A53T mutant animals [127, 128].